Literature DB >> 24599398

D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis.

Deborah Ducasse1, Laurent Boyer, Pierre Michel, Anderson Loundou, Alexandra Macgregor, Jean-Arthur Micoulaud-Franchi, Philippe Courtet, Mocrane Abbar, Marion Leboyer, Guillaume Fond.   

Abstract

RATIONALE AND
OBJECTIVE: The relationship between clinically effective antipsychotic drugs in obsessive-compulsive disorders (OCD) and binding affinities to cloned dopamine and serotonin receptor subtypes was analyzed in an effort to clarify the contribution of individual receptor subtypes to medication response.
METHODS: Meta-analysis was used to update previous meta-analyses of effectiveness data of add-on antipsychotic drugs to selective serotonin reuptake inhibitors (SSRIs) in OCD. Twelve previously analyzed randomized controlled trials (RCTs) and one new RCT were included. We performed a metaregression using a mixed-effect model to examine the association between antipsychotic's effectiveness and receptor affinity.
RESULTS: A total of 5 treatment arms obtained from 13 RCTs (431 patients) were included in our study. The results of our metaregression showed a significant association between D2 and D3 dopamine receptor affinities and effectiveness in OCD (respectively, slope = -0.36, p = 0.01; and slope = -0.50, p = 0.01) whereas other dopamine receptors and serotonin receptors were not significantly associated.
CONCLUSIONS: These observations suggest that increasing D2 and D3 dopamine receptor binding affinities enhances antipsychotics' effectiveness in obsessive-compulsive disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599398     DOI: 10.1007/s00213-014-3516-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Dopamine and serotonin receptor binding and antipsychotic efficacy.

Authors:  Neil M Richtand; Jeffrey A Welge; Aaron D Logue; Paul E Keck; Stephen M Strakowski; Robert K McNamara
Journal:  Neuropsychopharmacology       Date:  2007-01-24       Impact factor: 7.853

2.  Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

Authors:  M Atmaca; M Kuloglu; E Tezcan; O Gecici
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

Review 3.  Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

Authors:  Markus Dold; Martin Aigner; Rupert Lanzenberger; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2012-08-29       Impact factor: 5.176

4.  Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder.

Authors:  M Karayiorgou; C Sobin; M L Blundell; B L Galke; L Malinova; P Goldberg; J Ott; J A Gogos
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

Review 5.  Prevalence and incidence studies of anxiety disorders: a systematic review of the literature.

Authors:  Julian M Somers; Elliot M Goldner; Paul Waraich; Lorena Hsu
Journal:  Can J Psychiatry       Date:  2006-02       Impact factor: 4.356

6.  Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males.

Authors:  Damiaan Denys; Filip Van Nieuwerburgh; Dieter Deforce; Herman Westenberg
Journal:  Eur Neuropsychopharmacol       Date:  2006-01-19       Impact factor: 4.600

7.  A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.

Authors:  Juliana Belo Diniz; Roseli Gedanke Shavitt; Victor Fossaluza; Lorrin Koran; Carlos Alberto de Bragança Pereira; Euripedes Constantino Miguel
Journal:  J Clin Psychopharmacol       Date:  2011-12       Impact factor: 3.153

8.  Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Authors:  Alexander Bystritsky; Deborah L Ackerman; Richard M Rosen; Tanya Vapnik; Eda Gorbis; Karron M Maidment; Sanjaya Saxena
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

9.  Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder.

Authors:  Damiaan Denys; Froukje de Vries; Danielle Cath; Martijn Figee; Nienke Vulink; Dick J Veltman; Thalia F van der Doef; Ronald Boellaard; Herman Westenberg; Anton van Balkom; Adriaan A Lammertsma; Bart N M van Berckel
Journal:  Eur Neuropsychopharmacol       Date:  2013-07-19       Impact factor: 4.600

10.  Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.

Authors:  Ozmen Metin; Kemal Yazici; Senel Tot; Aylin Ertekin Yazici
Journal:  Hum Psychopharmacol       Date:  2003-08       Impact factor: 1.672

View more
  8 in total

Review 1.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

Review 2.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

3.  Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs.

Authors:  Jenni Vanhanen; Marja Kinnunen; Saara Nuutinen; Pertti Panula
Journal:  Psychopharmacology (Berl)       Date:  2014-10-12       Impact factor: 4.530

Review 4.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

5.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

6.  Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.

Authors:  Markus Dold; Martin Aigner; Rupert Lanzenberger; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2015-05-04       Impact factor: 5.176

Review 7.  Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment.

Authors:  Naomi A Fineberg; Annemieke M Apergis-Schoute; Matilde M Vaghi; Paula Banca; Claire M Gillan; Valerie Voon; Samuel R Chamberlain; Eduardo Cinosi; Jemma Reid; Sonia Shahper; Edward T Bullmore; Barbara J Sahakian; Trevor W Robbins
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

8.  Antipsychotics and OCD: Boon or Bane?

Authors:  Ahmed Naguy
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.